Humacyte (NASDAQ:HUMA) Stock

HUMACYTE INC

Humacyte

Humacyte Inc is developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues and organs designed to improve the lives of patients and transform the practice of medicine. It develops and manufactures acellular tissues to treat a wide range of diseases, injuries, and chronic conditions. Company's pipeline includes Vascular Trauma, PAD, Dailysis, Acellular Tissue Engineered Vessels, Advanced Organ Systems, Advanced Tissue Constructs.

Humacyte Inc

HUMAN PHEROMONE SCIENCE by Human Pheromone Sciences, Inc.

Human - United States Dollar

HUMAN HOLDINGS CO LTD by Human Holdings Co., Ltd.

Human Holdings Co Ltd

HUMAN UNITEC INTL INC by Human Unitec International, Inc.

Human Unitec International Inc

Humana Inc

Humanigen Inc

Humankind US Stock ETF

Humanscape

Humatech Inc

Kilvinane Wind Farm to Generate 8,500 MWh Annually, Strengthening Ireland's Energy Grid and Sustainability Goals
<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fameresco.com%2F&amp;esheet=54252403&amp;newsitemid=20250512305769&amp;lan=en-US&amp;anchor=Ameresco%2C+Inc.&amp;index=1&amp;md5=8923d4e903350cd8b488925bc9d82e29">Ameresco, Inc.</a>, (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AMRC#NYSE">AMRC</a>), a leading energy solutions provider dedicated to helping customers navigate the energy transition, today announced that its Irish subsidiary, Cork Sustainable Energy Limited (CSEL), has secured approval from An Bord Pleanála for a significant upgrade to the Kilvinane Wind Farm. This approval marks a pivotal step in enhancing Ireland's renewable energy infrastructure.
CSEL manages Kilvinane Wind Farm, located 8km East of Dunmanway, County Cork, which comprises of three turbines. The wind farm holds the capability to produce approximately 8,500 MWh of energy annually, supplying to the National Grid and contributing to Ireland's renewable energy targets as the second largest producer of wind energy in the world in terms of the share of electricity provided by wind energy.
An Bord Pleanála approved the wind farm upgrade, as it was designed to ensure consistency with the character of the structure and the neighboring structures. This decision provides greater clarity and certainty for wind farm operators and planning authorities regarding the planning implications of routine maintenance activities.

News

Global

AMRC

Ameresco's Irish Subsidiary, Cork Sustainable Energy Limited Secures Approval To Upgrade Kilvinane Wind Farm, Enabling Annual Generation Of 8,500 MWh To Strengthen Ireland's National Grid And Advance Sustainability Goals

HC Wainwright &amp; Co. analyst Andrew Fein maintains Structure Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GPCR#NASDAQ">GPCR</a>) with a Buy and lowers the price target from $80 to $75.

Price Target

Analyst Ratings

GPCR

HC Wainwright & Co. Maintains Buy on Structure Therapeutics, Lowers Price Target to $75

Jefferies analyst David Katz upgrades Marriott International (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MAR#NASDAQ">MAR</a>) from Hold to Buy and raises the price target from $226 to $303.

Upgrades

Jefferies Upgrades Marriott International to Buy, Raises Price Target to $303

ImmunoPrecise Antibodies Ltd. (IPA) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IPA#NASDAQ">IPA</a>) a leader in AI-driven biotherapeutics, is pleased to announce today new benchmarking results that validate the accuracy and utility of its in silico epitope mapping application, part of the LENSai&#x2122; platform, with a direct comparison to gold-standard wet-lab methods.
The results represent a notable advancement in computational biology, particularly in the field of antibody discovery, where high failure rates and costly, time-intensive experiments remain common industry challenges. LENSai's AI-powered platform was able to match the performance of x-ray crystallography—the industry's most precise but slowest and most expensive method—using sequence data alone.

ImmunoPrecise Announces Benchmarking Results For LENSai Epitope Mapping

WIIM

Sable Offshore shares are trading higher. The company reported Q1 financial results.

Earnings

PSNY

Polestar Q1 Retail Sales 12,304 Cars, Up 76.5% YoY

<ul>
<li>Company receives ISCT abstract award for the analytical characterization of its manufactured gamma-delta T cell therapies in the INB-100 trial, which has demonstrated durable, relapse-free survival in AML patients. &nbsp;</li>
<li>IN8bio's proprietary gamma-delta T cell manufacturing platform generates robust and reproducible products that are activated and primed for tumor cell killing, migration and immune cell recruitment. &nbsp;</li>
</ul>
NEW YORK, May 12, 2025 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=DB2yhXUoY-Ygc7UJXIHzObpDQdwo63iyjlW_wVNGtFk460i4jAnG6VXwX-4JfS1eebd9TRave9LWokSXv27QcA==">IN8bio, Inc</a>. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INAB#NASDAQ">INAB</a>), a clinical-stage biopharmaceutical company developing innovative gamma-delta (γδ) T cell therapies for cancer and autoimmune diseases, today announced new data on its proprietary γδ T manufacturing program. The oral presentation shared exciting updates about its unique manufacturing processes, including deep analytics, genomics and repertoire analysis, presented at the International Society for Cell &amp; Gene Therapy (ISCT) 2025 Annual Meeting. The data, which earned IN8bio the prestigious Host Region (U.S. East) Abstract Award, as presented by Bruce Levine, PhD, ISCT Past President and a member of IN8bio's Scientific Advisory Board. The award is a competitive recognition for scientific excellence and demonstrates how IN8bio's technology and know-how creates consistent, powerful cellular therapies.
The oral presentation highlights how IN8bio's DeltEx&#x2122;&nbsp;Allo manufacturing process consistently induces donor derived T cells to express γδ T cell receptors (TCRs) and genes, associated with increased cancer cytotoxicity. Gene expression profiling confirmed a highly potent product across multiple manufacturing batches.

Biotech

General

INAB

IN8bio Wins ISCT Abstract Award For Analytical Characterization Of Its Gamma-Delta T Cell Therapies In INB-100 AML Trial, Demonstrating Durable Relapse-Free Survival And Showcasing Consistent, Potent Anti-Cancer Activity Through Its Proprietary DeltEx Allo Manufacturing Platform

<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.lineagecell.com%2F&amp;esheet=54251920&amp;newsitemid=20250512395886&amp;lan=en-US&amp;anchor=Lineage+Cell+Therapeutics%2C+Inc.&amp;index=1&amp;md5=7ad2634e3c0f3cf1c635420efc88baed">Lineage Cell Therapeutics, Inc.</a> (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for serious neurological conditions, today announced that 36-month results from patients enrolled in a Phase 1/2a clinical study (ClinicalTrials.gov Identifier: <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fclinicaltrials.gov%2Fstudy%2FNCT02286089%3Fterm%3DNCT02286089&amp;esheet=54251920&amp;newsitemid=20250512395886&amp;lan=en-US&amp;anchor=NCT02286089&amp;index=2&amp;md5=f1b7e4c48b4121d7e35dd73fda550205">NCT02286089</a>) of RG6501 (<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Flineagecell.com%2Fproducts-pipeline%2Fopregen%2F&amp;esheet=54251920&amp;newsitemid=20250512395886&amp;lan=en-US&amp;anchor=OpRegen&amp;index=3&amp;md5=10f208040398ee823a0a9ba9cd01c062">OpRegen</a>) in patients with geographic atrophy (GA) secondary to age-related macular degeneration (AMD), will be presented at <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.ctsretina.org%2F&amp;esheet=54251920&amp;newsitemid=20250512395886&amp;lan=en-US&amp;anchor=Clinical+Trials+at+the+Summit+%28CTS%29+2025&amp;index=4&amp;md5=43930393293e7a220161901702f62a86">Clinical Trials at the Summit (CTS) 2025</a>. CTS will be held June 20 - 21, 2025, and brings together a diverse group of experts from around the world to discuss ongoing clinical trials and the latest data, all with the goal of achieving advances in vitreoretinal care. The presentation, "OpRegen&#xAE; Retinal Pigment Epithelium (RPE) Cell Therapy for Patients with Geographic Atrophy (GA): Month 36 Results from the Phase 1/2a Trial," will be presented by <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.cincinnatieye.com%2Fdoctors%2Fchristopher-d-riemann-m-d%2F&amp;esheet=54251920&amp;newsitemid=20250512395886&amp;lan=en-US&amp;anchor=Christopher+D.+Riemann%2C+M.D.&amp;index=5&amp;md5=6dcb39f18647f8051c2c92e86315a639">Christopher D. Riemann, M.D.</a>, Vitreoretinal Surgeon and Fellowship Director, <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.cincinnatieye.com%2F&amp;esheet=54251920&amp;newsitemid=20250512395886&amp;lan=en-US&amp;anchor=Cincinnati+Eye+Institute&amp;index=6&amp;md5=f6a2f47beb98662bcef7e6b929d70d75">Cincinnati Eye Institute</a> (CEI) and University of Cincinnati School of Medicine, on behalf of <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.roche.com%2F&amp;esheet=54251920&amp;newsitemid=20250512395886&amp;lan=en-US&amp;anchor=Roche&amp;index=7&amp;md5=7ea0dcbba540bacf936fd210913e76cd">Roche</a> and <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.gene.com%2F&amp;esheet=54251920&amp;newsitemid=20250512395886&amp;lan=en-US&amp;anchor=Genentech&amp;index=8&amp;md5=a3c44a4c1779d096ffd719d7c535780d">Genentech</a>, a member of the Roche Group.
 &nbsp;

LCTX

Lineage Cell Therapeutics Says RG6501 Phase 1/2a Clinical Study 36 Month Results To Be Featured At Clinical Trials At The Summit 2025

<h3>Gainers</h3>
<ul>
<li>Gryphon Digital Mining (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRYP#NASDAQ">GRYP</a>) shares moved upwards by 238.5% to $1.76 during Monday's pre-market session. The company's market cap stands at $122.0 million. </li>
<li>Next Technology Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NXTT#NASDAQ">NXTT</a>) shares moved upwards by 67.37% to $3.95. The market value of their outstanding shares is at $27.5 million. The company's, Q1 earnings came out yesterday. </li>
<li>Taoping (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TAOP#NASDAQ">TAOP</a>) shares rose 16.92% to $0.19. The market value of their outstanding shares is at $2.5 million. </li>
<li>Astera Labs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALAB#NASDAQ">ALAB</a>) stock moved upwards by 14.96% to $81.86. The market value of their outstanding shares is at $13.4 billion. As per the press release, Q1 earnings came out 4 days ago. </li>
<li>NextNav (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NN#NASDAQ">NN</a>) shares rose 14.71% to $15.05. The market value of their outstanding shares is at $1.9 billion. As per the news, the Q1 earnings report came out yesterday. </li>
<li>Argo Blockchain (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARBK#NASDAQ">ARBK</a>) shares increased by 14.18% to $0.42. The market value of their outstanding shares is at $26.5 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Abits Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABTS#NASDAQ">ABTS</a>) shares declined by 44.7% to $4.65 during Monday's pre-market session. The market value of their outstanding shares is at $11.0 million. </li>
<li>BTCS (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BTCS#NASDAQ">BTCS</a>) stock fell 31.19% to $2.14. The market value of their outstanding shares is at $42.9 million. </li>
<li>Infobird Co (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IFBD#NASDAQ">IFBD</a>) stock declined by 17.22% to $1.25. The market value of their outstanding shares is at $10.2 million. 
See Also: <a href="http://www.benzinga.com/money/tech-stocks/" title="www.benzinga.com/money/tech-stocks/">www.benzinga.com/money/tech-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Movers

ABTS

ALAB

ARBK

BTCS

GRYP

IFBD

Next Technology Holding Inc. - Ordinary Shares

NXTT

TAOP

9 Information Technology Stocks Moving In Monday's Pre-Market Session

<h3>Gainers</h3>
<ul>
<li>Noodles (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NDLS#NASDAQ">NDLS</a>) shares moved upwards by 17.9% to $1.0 during Monday's pre-market session. The company's market cap stands at $45.7 million. As per the news, the Q1 earnings report came out 3 days ago. </li>
<li>RH (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RH#NYSE">RH</a>) shares rose 17.91% to $229.09. The market value of their outstanding shares is at $4.2 billion. </li>
<li>Funko (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FNKO#NASDAQ">FNKO</a>) stock increased by 15.38% to $4.05. The company's market cap stands at $218.2 million. The company's, Q1 earnings came out 2 days ago. </li>
<li>LiveWire Gr (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LVWR#NYSE">LVWR</a>) stock moved upwards by 14.99% to $1.15. The company's market cap stands at $234.1 million. </li>
<li>GigaCloud Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GCT#NASDAQ">GCT</a>) shares increased by 14.89% to $16.66. The company's market cap stands at $634.2 million. As per the press release, Q1 earnings came out today. </li>
<li>Wayfair (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/W#NYSE">W</a>) stock rose 14.66% to $37.6. The company's market cap stands at $4.7 billion. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Superior Industries Intl (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SUP#NYSE">SUP</a>) shares fell 51.6% to $1.39 during Monday's pre-market session. The company's market cap stands at $40.1 million. As per the press release, Q1 earnings came out today. </li>
<li>MEDIROM Healthcare Techs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRM#NASDAQ">MRM</a>) shares decreased by 20.82% to $0.72. The company's market cap stands at $5.7 million. </li>
<li>Zapp Electric Vehicles Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZAPP#NASDAQ">ZAPP</a>) shares declined by 13.34% to $0.35. The company's market cap stands at $2.7 million. </li>
<li>Hour Loop (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOUR#NASDAQ">HOUR</a>) stock fell 9.1% to $1.2. The company's market cap stands at $42.1 million. </li>
<li>Kaixin Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KXIN#NASDAQ">KXIN</a>) stock declined by 7.0% to $0.93. The market value of their outstanding shares is at $1.6 million. 
See Also: <a href="http://www.benzinga.com/money/best-consumer-cyclical-stocks/" title="www.benzinga.com/money/best-consumer-cyclical-stocks/">www.benzinga.com/money/best-consumer-cyclical-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

FNKO

HOUR

KXIN

LVWR

NDLS

ZAPP

11 Consumer Discretionary Stocks Moving In Monday's Pre-Market Session

DA Davidson analyst Peter Heckmann upgrades ACI Worldwide (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACIW#NASDAQ">ACIW</a>) from Neutral to Buy and maintains the price target from $60 to $60.

ACIW

DA Davidson Upgrades ACI Worldwide to Buy, Maintains Price Target to $60

<h3>Gainers</h3>
<ul>
<li>Jayud Global Logistics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JYD#NASDAQ">JYD</a>) stock increased by 133.8% to $0.51 during Monday's pre-market session. The company's market cap stands at $47.8 million. </li>
<li>Clean Energy Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CETY#NASDAQ">CETY</a>) shares rose 18.14% to $0.54. The market value of their outstanding shares is at $25.6 million. </li>
<li>ZIM Integrated Shipping (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZIM#NYSE">ZIM</a>) stock increased by 13.98% to $16.27. The company's market cap stands at $1.9 billion. </li>
<li>Stanley Black &amp; Decker (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SWK#NYSE">SWK</a>) stock increased by 13.29% to $71.0. The market value of their outstanding shares is at $10.9 billion. </li>
<li>Dragonfly Energy Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DFLI#NASDAQ">DFLI</a>) shares moved upwards by 13.04% to $0.52. The company's market cap stands at $3.8 million. </li>
<li>Freightos (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRGO#NASDAQ">CRGO</a>) stock increased by 12.38% to $2.36. The market value of their outstanding shares is at $118.1 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Nuvve Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVVE#NASDAQ">NVVE</a>) stock declined by 40.3% to $1.66 during Monday's pre-market session. The market value of their outstanding shares is at $5.0 million. </li>
<li>Vast Renewables (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VSTE#NASDAQ">VSTE</a>) shares decreased by 20.36% to $0.11. The company's market cap stands at $3.3 million. </li>
<li>Lakeside Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LSH#NASDAQ">LSH</a>) shares declined by 11.07% to $0.82. The market value of their outstanding shares is at $6.1 million. </li>
<li>Intelligent Living (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ILAG#NASDAQ">ILAG</a>) stock declined by 10.9% to $0.45. The company's market cap stands at $8.1 million. </li>
<li>Alta Equipment Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ALTG#NYSE">ALTG</a>) stock declined by 10.49% to $4.1. The market value of their outstanding shares is at $136.0 million. The company's, Q1 earnings came out 3 days ago. 
See Also: <a href="http://www.benzinga.com/money/best-industrials-stocks/" title="www.benzinga.com/money/best-industrials-stocks/">www.benzinga.com/money/best-industrials-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ALTG

CETY

CRGO

DFLI

ILAG

NVVE

VSTE

11 Industrials Stocks Moving In Monday's Pre-Market Session

<h3>Gainers</h3>
<ul>
<li>Kindly MD (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KDLY#NASDAQ">KDLY</a>) stock increased by 454.4% to $21.62 during Monday's pre-market session. The company's market cap stands at $129.2 million. </li>
<li>CytomX Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTMX#NASDAQ">CTMX</a>) shares increased by 64.79% to $1.53. The company's market cap stands at $122.5 million. As per the press release, Q1 earnings came out today. </li>
<li>Avalo Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVTX#NASDAQ">AVTX</a>) stock moved upwards by 30.54% to $5.3. The company's market cap stands at $56.5 million. As per the press release, Q1 earnings came out today. </li>
<li>Regencell Bioscience (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGC#NASDAQ">RGC</a>) shares increased by 29.76% to $474.95. The company's market cap stands at $6.1 billion. </li>
<li>Akso Health (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AHG#NASDAQ">AHG</a>) shares moved upwards by 19.26% to $1.68. The company's market cap stands at $670.0 million. </li>
<li>Kairos Pharma (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/KAPA#AMEX">KAPA</a>) stock rose 17.16% to $0.8. The company's market cap stands at $13.6 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>SCWorx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WORX#NASDAQ">WORX</a>) shares fell 20.0% to $0.48 during Monday's pre-market session. The market value of their outstanding shares is at $1.1 million. </li>
<li>Longevity Health Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XAGE#NASDAQ">XAGE</a>) shares decreased by 15.76% to $0.13. The market value of their outstanding shares is at $3.8 million. </li>
<li>Gyre Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GYRE#NASDAQ">GYRE</a>) shares declined by 10.5% to $8.53. The market value of their outstanding shares is at $799.6 million. As per the press release, Q1 earnings came out yesterday. </li>
<li>Apimeds Pharmaceuticals (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/APUS#AMEX">APUS</a>) shares fell 10.01% to $1.98. The company's market cap stands at $25.1 million. </li>
<li>Edgewise Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EWTX#NASDAQ">EWTX</a>) stock declined by 9.68% to $13.17. The market value of their outstanding shares is at $1.3 billion. As per the press release, Q1 earnings came out 2 days ago. </li>
<li>Wellgistics Health (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WGRX#NASDAQ">WGRX</a>) shares fell 9.22% to $2.46. The company's market cap stands at $176.7 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

APUS

AVTX

CTMX

EWTX

GYRE

KAPA

KDLY

WGRX

WORX

Longevity Health Holdings, Inc. - Common Stock

XAGE

12 Health Care Stocks Moving In Monday's Pre-Market Session

ENPH

Enphase Energy Launches Enphase IQ Balcony Solar System In Belgium

Esperion (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ESPR#NASDAQ">ESPR</a>) today announced that it has entered into a settlement agreement with Micro Labs USA, Inc. and its affiliate Micro Labs Limited (together, Micro Labs). This agreement resolves the patent litigation brought by Esperion against Micro Labs in response to Micro Labs' Abbreviated New Drug Application (ANDA) seeking approval to market a generic version of NEXLETOL prior to the expiration of the applicable patents. Pursuant to the agreement, Micro Labs has agreed not to market a generic version of NEXLETOL in the United States prior to April 19, 2040, unless certain limited circumstances customarily included in these types of agreements occur.
The pending patent litigation against the remaining defendants (Accord Healthcare Inc; Alkem Laboratories Ltd.; Aurobindo Pharma Limited (along with an affiliate); Dr. Reddy's Laboratories Inc. (along with an affiliate); Hetero USA Inc. (along with affiliates); MSN Pharmaceuticals Inc. (along with an affiliate); Renata Limited; and Sandoz Inc.) is ongoing, and there can be no assurance whether such ongoing patent litigation will allow a generic version of NEXLETOL and/or NEXLIZET, as applicable, to be marketed in the U.S. prior to April 19, 2040.

ESPR

Esperion Settles Patent Litigation with Micro Labs, Preventing Generic NEXLETOL Launch Before 2040

Liberty Braves Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BATRK#NASDAQ">BATRK</a>) reported quarterly losses of $(0.66) per share which beat the analyst consensus estimate of $(0.84) by 21.43 percent. This is a 20.48 percent increase over losses of $(0.83) per share from the same period last year. The company reported quarterly sales of $47.21 million which beat the analyst consensus estimate of $37.00 million by 27.60 percent. This is a 27.32 percent increase over sales of $37.08 million the same period last year.

Earnings Beats

BATRK

Liberty Braves Group Q1 EPS $(0.66) Beats $(0.84) Estimate, Sales $47.21M Beat $37.00M Estimate

Company Urges Stockholders to Vote FOR Reverse Stock Split Proposal at Upcoming Annual Meeting to Avoid Nasdaq Delisting
SOUTH SAN FRANCISCO, Calif., May 12, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VXRT#NASDAQ">VXRT</a>) today addresses frequently asked stockholder questions regarding a reverse stock split proposal at the Company's Annual Meeting taking place on Wednesday, May 21, 2025, to regain Nasdaq compliance.
1)&nbsp;&nbsp; Why is Vaxart proposing a reverse stock split?
a.&nbsp;&nbsp;&nbsp;Vaxart is at risk of being delisted from Nasdaq since the Company's share price is not in compliance with their minimum $1.00 bid price requirement. A reverse split of the Company's common stock enables Vaxart to regain compliance and helps to ensure that the Company's common stock can remain listed on Nasdaq.
2)&nbsp;&nbsp; Will the Reverse Stock Split change the value of my investment?
a.&nbsp;&nbsp;&nbsp;No. The reverse stock split does not impact the aggregate value of a stockholder's investment or percentage ownership interest in the Company, except with respect to the treatment of fractional shares. Stockholders will own fewer shares at an anticipated higher price per share.
3)&nbsp;&nbsp; Will the Reverse Stock Split cause dilution in Vaxart's stock?
a.&nbsp;&nbsp;&nbsp;No. The reverse split only causes a change for all issued shares of Vaxart's common stock uniformly.
4)&nbsp;&nbsp; Why is the proposed Reverse Stock Split ratio of not less than 1-for-5 and not more than 1-for-50 so wide?
a.&nbsp;&nbsp;&nbsp;Since the closing per share stock price was $0.42 as of Friday, May 9, 2025, the Company has no present intention of effecting a reverse stock split as high as 1:50. The board of directors intends to select a ratio for the reverse stock split only high enough as it deems necessary to resolve the Nasdaq deficiency. Of course, Vaxart prefers the requirement to be satisfied through appreciation of Vaxart's stock price and, if our stock closes above $1.00 in the timeframe required and continues trading above $1.00, the board of directors may decide not to effect the reverse stock split even if it has been approved.

Stock Split

VXRT

Vaxart Urges Stockholders To Vote 'FOR' Reverse Stock Split Proposal Of Not Less Than 1-For-5 And Not More Than 1-For-50 At Upcoming Annual Meeting On May 21, 2025 To Avoid Nasdaq Delisting

Southwest Gas Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SWX#NYSE">SWX</a>) reported quarterly earnings of $1.65 per share which beat the analyst consensus estimate of $1.50 by 10 percent. This is a 20.44 percent increase over earnings of $1.37 per share from the same period last year. The company reported quarterly sales of $1.30 billion which missed the analyst consensus estimate of $1.50 billion by 13.35 percent. This is a 18.03 percent decrease over sales of $1.58 billion the same period last year.

Earnings Misses

Southwest Gas Hldgs Q1 Adj. EPS $1.65 Beats $1.50 Estimate, Sales $1.30B Miss $1.50B Estimate

Argus Research analyst John Staszak upgrades Wayfair (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/W#NYSE">W</a>) from Hold to Buy and announces $40 price target.

Argus Research Upgrades Wayfair to Buy, Announces $40 Price Target

Barrington Research analyst Michael Petusky downgrades ModivCare (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MODV#NASDAQ">MODV</a>) from Outperform to Market Perform.

Downgrades

MODV

Barrington Research Downgrades ModivCare to Market Perform

Health Care

Legal

Press Releases

Humacyte Announces Issuance of U.S. Patent Covering Manufacturing of Symvess™ and Other Bioengineered Tissues

Humacyte to Present at the TD Cowen 45th Annual Health Care Conference

Humacyte to Host In-Person and Virtual Investor Event in New York to Discuss Commercial Launch of Symvess™ (acellular tissue engineered vessel-tyod) for Extremity Vascular Trauma on March 6, 2025

Trestle Bio Announces Research Collaboration with Humacyte

Humacyte Announces Publication of the Budget Impact Model (BIM) for Symvess™ (acellular tissue engineered vessel-tyod) in the Journal of Medical Economics

Financing

Humacyte, Inc. Announces Proposed Public Offering of Common Stock

Humacyte, Inc. Announces Pricing of Public Offering of Common Stock

Humacyte to Present Fourth Quarter and Full Year Financial Results and Provide Corporate Update on March 28, 2025

Humacyte Announces Fourth Quarter and Year End 2024 Financial Results and Provides Business Update

Humacyte to Present First Quarter Financial Results and Provide Corporate Update on May 13, 2025

Comments

Humacyte

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL